Adriana Marques

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Chronic Lyme disease: a review
    Adriana Marques
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Infect Dis Clin North Am 22:341-60, vii-viii. 2008
  2. ncbi request reprint Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates
    Rendi Murphree Bacon
    Division of Vector Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA
    J Infect Dis 187:1187-99. 2003
  3. ncbi request reprint Lyme disease: an update
    A R Marques
    Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N228, 10 Center Drive, Bethesda, MD 20892 1888, USA
    Curr Allergy Asthma Rep 1:541-9. 2001
  4. pmc Evaluation of the C6 peptide enzyme-linked immunosorbent assay for individuals vaccinated with the recombinant OspA vaccine
    Adriana R Marques
    Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Microbiol 40:2591-3. 2002
  5. doi request reprint Lyme disease: a review
    Adriana R Marques
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11 N234, Bethesda, MD 20892, USA
    Curr Allergy Asthma Rep 10:13-20. 2010
  6. pmc Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls
    Adriana Marques
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Clin Vaccine Immunol 16:1249-50. 2009
  7. pmc Detection of immune complexes is not independent of detection of antibodies in Lyme disease patients and does not confirm active infection with Borrelia burgdorferi
    Adriana R Marques
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1888, USA
    Clin Diagn Lab Immunol 12:1036-40. 2005
  8. pmc Rapid, simple, quantitative, and highly sensitive antibody detection for lyme disease
    Peter D Burbelo
    Neurobiology and Pain Therapeutics Section, 49 Convent Drive, Building 49, Room 1C20, NIDCR, NIH, Bethesda, MD 20892 4410, USA
    Clin Vaccine Immunol 17:904-9. 2010
  9. pmc Cerebrospinal fluid-infiltrating CD4+ T cells recognize Borrelia burgdorferi lysine-enriched protein domains and central nervous system autoantigens in early lyme encephalitis
    Jan D Lunemann
    Neuroimmunology Branch, Cellular Immunology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Infect Immun 75:243-51. 2007
  10. pmc Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae
    Harald Gelderblom
    Cellular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Clinical Studies Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Am J Pathol 170:251-62. 2007

Detail Information

Publications20

  1. pmc Chronic Lyme disease: a review
    Adriana Marques
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Infect Dis Clin North Am 22:341-60, vii-viii. 2008
    ..Further research to elucidate the mechanisms underlying persistent symptoms after Lyme disease and controlled trials of new approaches to the treatment and management of these patients are needed...
  2. ncbi request reprint Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates
    Rendi Murphree Bacon
    Division of Vector Borne Infectious Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA
    J Infect Dis 187:1187-99. 2003
    ..burgdorferi in patients with acute erythema migrans. In later stages of Lyme disease, the sensitivities of the in parallel tests and 2-tiered testing were high and statistically equivalent...
  3. ncbi request reprint Lyme disease: an update
    A R Marques
    Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11N228, 10 Center Drive, Bethesda, MD 20892 1888, USA
    Curr Allergy Asthma Rep 1:541-9. 2001
    ....
  4. pmc Evaluation of the C6 peptide enzyme-linked immunosorbent assay for individuals vaccinated with the recombinant OspA vaccine
    Adriana R Marques
    Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Microbiol 40:2591-3. 2002
    ..The C6 peptide ELISA can be used to diagnose Lyme disease in patients who have received the OspA vaccine...
  5. doi request reprint Lyme disease: a review
    Adriana R Marques
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11 N234, Bethesda, MD 20892, USA
    Curr Allergy Asthma Rep 10:13-20. 2010
    ..This article reviews the pathogenesis, epidemiology, clinical manifestations, diagnosis, treatment, and prevention of Lyme disease...
  6. pmc Natural killer cell counts are not different between patients with post-Lyme disease syndrome and controls
    Adriana Marques
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA
    Clin Vaccine Immunol 16:1249-50. 2009
    ..We performed immunophenotyping in 9 individuals with post-Lyme disease syndrome, 12 who recovered from Lyme disease, and 9 healthy volunteers. The number of natural killer cells was not significantly different between the groups...
  7. pmc Detection of immune complexes is not independent of detection of antibodies in Lyme disease patients and does not confirm active infection with Borrelia burgdorferi
    Adriana R Marques
    Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1888, USA
    Clin Diagn Lab Immunol 12:1036-40. 2005
    ..burgdorferi in PEG-IC preparations is not more likely to reflect active infection than testing in unprocessed serum and should not be used in individuals who received the OspA vaccine...
  8. pmc Rapid, simple, quantitative, and highly sensitive antibody detection for lyme disease
    Peter D Burbelo
    Neurobiology and Pain Therapeutics Section, 49 Convent Drive, Building 49, Room 1C20, NIDCR, NIH, Bethesda, MD 20892 4410, USA
    Clin Vaccine Immunol 17:904-9. 2010
    ..These results suggest that screening by the LIPS test with VOVO and other B. burgdorferi antigens offers an efficient quantitative approach for evaluation of the antibody responses in patients with Lyme disease...
  9. pmc Cerebrospinal fluid-infiltrating CD4+ T cells recognize Borrelia burgdorferi lysine-enriched protein domains and central nervous system autoantigens in early lyme encephalitis
    Jan D Lunemann
    Neuroimmunology Branch, Cellular Immunology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Infect Immun 75:243-51. 2007
    ..burgdorferi-specific T cells is not restricted to chronic and treatment-resistant manifestations...
  10. pmc Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae
    Harald Gelderblom
    Cellular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Clinical Studies Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Am J Pathol 170:251-62. 2007
    ..IL-10 injected systemically reduced disease and spirochetemia. The results suggest IL-10 plays a protective role as a down-regulator of inflammation and pathogen load during infection with relapsing fever spirochetes...
  11. pmc Lack of serum antibodies against Borrelia burgdorferi in children with autism
    Peter D Burbelo
    Neurobiology and Pain Therapeutics Section, Laboratory of Sensory Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA
    Clin Vaccine Immunol 20:1092-3. 2013
    ..No seropositivity against Borrelia burgdorferi was detected in the children with and without autism. There was no evidence of an association between Lyme disease and autism. ..
  12. ncbi request reprint Borrelia burgdorferi Induces TLR1 and TLR2 in human microglia and peripheral blood monocytes but differentially regulates HLA-class II expression
    Riccardo Cassiani-Ingoni
    Cellular Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20892, USA
    J Neuropathol Exp Neurol 65:540-8. 2006
    ..burgdorferi can elicit opposite immunoregulatory effects in blood and in brain immune cells, which could play a role in the different susceptibility of these compartments to infection...
  13. pmc Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States
    Jeffrey I Cohen
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Bethesda, MD 20892, USA
    Blood 117:5835-49. 2011
    ..These studies are registered at http://www.clinicaltrials.gov as NCT00032513 for CAEBV, NCT00062868 and NCT00058812 for EBV-specific T-cell studies, and NCT00578539 for the hematopoietic stem cell transplantation protocol...
  14. pmc Synthesis and antigenicity of BBGL-2 glycolipids of Borrelia burgdorferi, the causative agent of Lyme disease
    Vince Pozsgay
    Program on Developmental and Molecular Immunity, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 20892 2423, United States
    Carbohydr Res 346:1551-63. 2011
    ..This substance proved to be antigenic and is considered a candidate vaccine for Lyme disease...
  15. ncbi request reprint Audiologic manifestations of patients with post-treatment Lyme disease syndrome
    Lawrence I Shotland
    Hearing Section, Neuro Otology Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland, USA
    Ear Hear 24:508-17. 2003
    ..The purpose of this study was to characterize auditory function in patients diagnosed with post-treatment Lyme disease syndrome (PTLDS)...
  16. ncbi request reprint Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders
    Paolo A Muraro
    Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, MD 20892 1400, USA
    Brain 126:20-31. 2003
    ....
  17. pmc Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers
    Yo Hoshino
    Medical Virology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 83:11857-61. 2009
    ..Valacyclovir reduces the frequency of EBV-infected B cells when administered over a long period and, in theory, might allow eradication of EBV from the body if reinfection does not occur...
  18. pmc C6 test as an indicator of therapy outcome for patients with localized or disseminated lyme borreliosis
    Mario T Philipp
    Division of Bacteriology and Parasitology, Tulane National Primate Research Center, Tulane University Health Sciences Center, Covington, Louisiana 70433, USA
    J Clin Microbiol 41:4955-60. 2003
    ..0003). These results suggest that a change in the anti-C(6) antibody titer may serve as an indicator of therapy outcome for patients with localized or disseminated Lyme borreliosis...
  19. pmc A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme Borreliosis
    Mario T Philipp
    Department of Bacteriology and Parasitology, Tulane National Primate Research Center, Tulane University Health Sciences Center, Covington, LA 70433, USA
    Clin Diagn Lab Immunol 12:1069-74. 2005
    ..0001). These results indicate that a decline in anti-C(6) antibody titer coincides with effective antimicrobial therapy in patients with early localized or early disseminated Lyme borreliosis...
  20. ncbi request reprint Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes
    Erik S Cabral
    Clinical Studies Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 1888, USA
    J Infect Dis 193:849-59. 2006
    ..These results indicate that diverse stimuli can cause differential TLR expression, and we hypothesize that these changes may be useful for either the pathogen and/or the host...